Open AccessThe Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers
Author(s) -
Hanna Glenn J.,
Bae Ji Eun,
Lorch Jochen H.,
Haddad Robert I.,
Jo Vickie Y.,
Schoenfeld Jonathan D.,
Margalit Danielle N.,
Tishler Roy B.,
Goguen Laura A.,
Annino Donald J.,
Chau Nicole G.
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2019-0841
Subject(s) - medicine , trastuzumab , salivary duct carcinoma , adenoid cystic carcinoma , adjuvant , oncology , her2/neu , salivary gland , immunostaining , adjuvant therapy , immunohistochemistry , pathology , carcinoma , cancer , breast cancer
Background Although high‐grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER‐2/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER‐2 directed therapy in the high‐risk postoperative setting and explored the clinical utility of sequentially targeting these receptors in the setting of advanced disease. Materials and Methods We clinically annotated 95 patients with SGC (excluding adenoid cystic carcinoma) treated at our institution from 2002 to 2019 and recorded AR, HER‐2/neu status, and tumor genomic profiling results when available. Clinicopathologic information was then integrated with outcomes. Results Of 95 patients, most had high‐risk histologies, with salivary duct carcinoma (SDC) as the most frequent diagnosis (43, 45%). Thirty‐five (37%) experienced recurrence (51% SDC). HER‐2/neu was positive (1–3+) by immunostaining in 34 of 52 (65%) evaluable cases. There was no difference in survival based on HER‐2/neu or AR expression. Nine of 17 (53%) patients with HER‐2+ SDC received adjuvant chemoradiation with trastuzumab. Median disease‐free survival (DFS) and overall survival (OS) were longer among patients with HER‐2/neu 3+ staining tumors who received adjuvant trastuzumab versus those who did not (DFS, 117 vs. 9 months; p = .02; OS, 74 vs. 43 months; p = .02), with no difference among other HER‐2/neu subgroups (0–2+). Two of nine (22%) patients treated with adjuvant trastuzumab demonstrated recurrence, both with low HER‐2/neu staining intensity (1+). Longer time to recurrence (hazard ratio, 0.94; p = .01) predicted improved outcomes. Both androgen deprivation and HER‐2‐directed therapies had clinical benefit beyond the first‐line metastatic setting, with partial response observed beyond second‐line use. Conclusion Although prospective data are lacking, the use of adjuvant trastuzumab in high‐risk patients with SGC appears beneficial, particularly among patients with tumors exhibiting HER‐2/neu 3+ immunostaining. Implications for Practice Results of this study showed an improved disease‐free and overall survival in patients treated with adjuvant trastuzumab for high‐risk salivary gland cancers with strong HER‐2/neu staining intensity. Following recurrence or metastatic spread, sequential HER‐2, and androgen‐directed therapies may benefit certain patients with salivary gland cancer.